WovenEndoBridge™ 17 Aneurysm Embolization System – Terumo Neuro’s Pioneering Device for Treating Ruptured Aneurysms Approved in Japan

WovenEndoBridge™ 17 Aneurysm Embolization System – Terumo Neuro’s Pioneering Device for Treating Ruptured Aneurysms Approved in Japan

With more than 15 years of clinical data, the WovenEndoBridge™ System is transforming the treatment of patients with complex aneurysms

Tokyo, Japan – May 1, 2026 – Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the launch of the WovenEndoBridge™ 17 Aneurysm Embolization System in Japan, expanding treatment options for patients with ruptured and unruptured intracranial aneurysms. The WovenEndoBridge 17 System received regulatory approval in Japan in November 2025.

The WovenEndoBridge 17 System is a single device, intrasaccular treatment designed to seal the aneurysm neck and protect the dome in wide neck bifurcation aneurysms. Building on more than 15 years of clinical experience with the WovenEndoBridge System, it represents the latest evolution of a technology that has helped advance the standard of care for thousands of patients worldwide since its initial introduction in 2010—reshaping how physicians treat complex aneurysms.

“With the introduction of the WovenEndoBridge 17 System, it has become possible to provide safer treatment for off-axis aneurysms, shallow-basined aneurysms, and small aneurysms—cases for which the conventional WovenEndoBridge 21 System offered only limited applicability,” said Pf.. Akira ISHII, Juntendo University Hospital. “As a result, the indications for treatment with the WovenEndoBridge System have expanded, and it is expected to become the first-line option for bifurcation aneurysms going forward. In addition, the WovenEndoBridge 17 System offers significantly improved operability compared with the previous generation, underscoring Terumo’s high level of technological capability and accelerating the future adoption of therapy with the WovenEndoBridge System.”

Cerebral aneurysms affect approximately 3.2% of the global population, most commonly presenting around age 50. While prevalence is similar between men and women overall, rates shift toward women later in life, approaching a 2:1 ratio after age 50. Each year, aneurysm rupture leading to subarachnoid hemorrhage (SAH) occurs in approximately 1 per 10,000 people, with higher incidence reported in Finnish and Japanese populations.ⁱ

“We are extremely proud to be launching the WovenEndoBridge 17 System in Japan,” said Hiroshi Tada, General Manager, Terumo Neuro in Japan. “This clinically proven solution expands physicians’ treatment options for patients with complex aneurysms and reflects our continued commitment to advancing neurovascular care through meaningful innovation.”

The WovenEndoBridge Aneurysm Embolization System has been shown to be a safe and effective treatment for both ruptured and unruptured aneurysms with 0% rebleeding after initial procedure and WovenEndoBridge related morbidity.ⁱⁱ*

It provides the following benefits:

• When placed inside the aneurysm sac, the WovenEndoBridge System’s proprietary Microbraid™ technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment. ⁱⁱⁱ

• With one intrasaccular device, the WovenEndoBridge System provides reduced procedure times with streamlined treatment method and less radiation exposure. ^iv, ^v, ^vi, ^vii

High metal coverage (~60%) at the proximal and distal ends disrupts flow at the aneurysm neck and dome ^viii

About Wide Neck Bifurcation Aneurysms

An intracranial aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain. A weakness located at a junction between two diverging vessels is called a bifurcation aneurysm.

Important Information About the WovenEndoBridge Aneurysm Embolization System

The WovenEndoBridge Aneurysm Embolization System is a unique, single-device treatment solution for wide neck bifurcation aneurysms, which may account for up to 35% of all aneurysms. When placed inside the aneurysm sac, the WovenEndoBridge system proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment. The pivotal WovenEndoBridge Intrasaccular Therapy Trial (WovenEndoBridge -IT) demonstrated that the WovenEndoBridge System is effective in attaining positive long-term clinical results in a safe, single-device procedure for wide neck bifurcation aneurysms.

The WovenEndoBridge Aneurysm Embolization System has been CE marked since 2010 and has been used to treat more than 65,000 patients and in multiple clinical studies around the world. The WovenEndoBridge Aneurysm Embolization system is indicated for use in the endovascular treatment of wide-neck intracranial aneurysms (defined as a neck size of 4mm or greater, or a dome/neck ratio of less than 2) located at the bifurcation in either the anterior or posterior circulation.

For more information, contact:

Rebecca Janzon, Terumo Neuro
Email: Rebecca.janzon@microvention.com
Phone: +1 949.685.4391

About Terumo Neuro

We’re in business to create and deliver innovations that redefine what’s possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro products are sold in more than seventy countries through a dedicated sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.

For more information, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio—from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products.

*The CLEVER and CLARYS studies were conducted in accordance with the European indications for use.

References:

Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into. Intended for Healthcare Professionals audience Only. Class III CE Marked: 0297. www.terumoneuro.com